桂枝茯苓丸治疗肩痛:随机等待列表对照预试验方案
本研究为双中心、随机、等待列表对照预试验,计划招募40例伴有血瘀证(血瘀评分≥9)且肩痛VAS≥4、甘油三酯≥150 mg/dl或总胆固醇≥200 mg/dl的受试者,比较即刻使用桂枝茯苓丸8周与等待8周后用药对肩痛及血瘀相关指标的影响,为后续全面临床试验提供依据。
要点
- 桂枝茯苓丸组予8周治疗,等待组在8周对照等待后于第8-16周接受治疗。
- 主要结局为肩痛,次要结局含血瘀评分、血压、ABI、baPWV及血脂等。
- 本研究为预试验,结果将用于设计后续全面临床试验。
核心结论
- 本预试验旨在探索桂枝茯苓丸对血瘀相关肩部不适的治疗效果,结果将为全面临床试验提供基础。
研究设计与样本
- 研究为双中心、随机、等待列表对照预试验,计划从两所大学医院招募40例受试者,随机分配至即刻治疗组和等待治疗组。
主要发现
- 原文未报告研究结果,仅报告研究设计与结局指标。
关键数值与推荐
- 纳入标准包括肩痛且视觉模拟量表(VAS)评分≥4分(满分10分)、血瘀评分≥9分,以及甘油三酯≥150 mg/dl或总胆固醇≥200 mg/dl。
- 即刻治疗组入组后接受桂枝茯苓丸治疗8周;等待治疗组在8周对照等待后于第8-16周接受治疗。
- 主要结局为肩痛;次要结局包括血瘀评分、血压、踝臂压力指数(ABI)、臂踝脉搏波传导速度(baPWV)、体重指数、腰围、血氧测定指标,以及血脂、血糖、抵抗素、C反应蛋白、血清淀粉样P物质和D-二聚体水平。
临床怎么用
- 本研究为预试验,尚不能提供临床实践推荐,其结果将用于设计后续全面临床试验。
局限性
- 原文未报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shoulder pain is an uncomfortable feeling in the muscle around the shoulder. The cause of myalgia is the accumulation of lactic acid in muscles and impaired blood circulation, which is called blood stasis in traditional East Asian medicine. This study aimed to explore the therapeutic effect of Gyejibongnyeong-Hwan (GBH) for shoulder discomfort related to blood stasis before and after treatment. METHODS/DESIGN: This study will be a double-centre, randomised, wait-list controlled pilot trial. Participants with shoulder pain and with a visual analogue scale score of 4 or higher out of 10, blood stasis score of 9 or higher, and triglyceride level of ≥150 mg/dl or total cholesterol level of ≥200 mg/dl will be recruited from two university hospitals. A total of 40 participants will be assigned to the immediate and waiting treatment groups. The immediate treatment group will receive GBH for 8 weeks on enrolment while the waiting treatment group will receive GBH for 8-16 weeks after 8 weeks of controlled waiting. The primary outcome is shoulder pain, and the secondary outcomes are the blood stasis score, blood pressure, ankle-brachial pressure index, brachial-ankle pulse wave velocity, body mass index, waist circumference, indexes of oximetry, and levels of blood lipid, blood sugar, resistin, C-reactive protein, serum amyloid P, and D-dimer. DISCUSSION: The results of this pilot trial will be the bases for a full-scale clinical trial of GBH. TRIAL REGISTRATION: Clinical Research Information Service, KCT0003837. Registered on 23 April 2019. https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14258.
引用
- Jang S, Sung HK, Ko MM, et al. Effectiveness of Gyejibongnyeong-Hwan for shoulder pain: study protocol for a randomised, wait-list controlled pilot trial. Trials. 2020. PMID: 32066487. doi:10.1186/s13063-020-4092-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。